Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 19-Feb-2014

Torigen Pharmaceuticals, Inc.


Torigen Pharmaceuticals is commercializing technology out of the University of Notre Dame focused on bringing an innovative cancer therapy "to the dogs." VetiVax is a veterinary cancer treatment personalized to the animal’s own tumor cells and prepared in office by any veterinarian. The product’s ease-of-use coupled with a disruptive business model, allows us to reach 40,000 veterinarians nationwide, rather than restriction to only specialist veterinary oncologists. Torigen’s patent portfolio is strategically protected both domestically and internationally. In tandem with an integrative business model, our product offers a sustainable competitive advantage leading to a strategic market launch.


Additional Questions

Who is your customer?

Local veterinarians have the capability of treating cancer in their own office if they were presented with the correct products. VetiVax hopes to sell their product to the 40,000 local veterinary clinics nationwide creating a disruptive product. We have validated our market size with veterinary oncologists and veterinarians around the country and picked three common types of cancer; mammary carcinoma, oral melanoma, and squamous cell carcinoma. These tumor types are palpable, aggressive, and currently lack different treatment modalities. Our surveys have shown that we have a TAM of at least 120,000 cases per year. These cancer types have immunogenic properties which has allowed us to prove the efficacy of our treatment in multiple anecdotal cases.

What problem does this idea/product solve or what market need does it serve?

Each year, over 1.2 millions dogs are diagnosed with cancer and nearly 50% will die from their disease. Chemotherapy and radiation are the standard of care treatment options, but these are expensive (costing between $3,500-$10,000) and often have severe side effects. The veterinary market is calling out for a product that is affordable, effective, and lacks the severe negative side effects associated with chemotherapy and radiation.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Our product, VetiVax, is a kit that contains all of the components necessary for a veterinarian to make a personalized cancer vaccine in their own office. In only one hour, an animal can be given an injection that is specifically directed at killing their cancerous cells.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

Our team is composed of the most motivated, determined, and committed individuals you will ever find. Co-founded by Ashley Kalinauskas, Dr. Mark Suckow, Conor O'Donoghue, and Tom Collins, we were able to take an amazing technology and develop a commercialization plan that could revolutionize how veterinary cancer is treated.